Tests intensive versus liberal phosphate targets in adults on dialysis for kidney failure
Compares two blood phosphate targets in adults with kidney failure receiving dialysis.
Plain-language title generated from the registry record
Registry title: Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
Key facts
- Where
- Calgary, Edmonton, Halifax, Kingston, London, Longueuil, Montreal, North York, Oakville, Orillia, Oshawa, Ottawa, Québec, Red Deer, Regina, Richmond Hill, Scarborough Village, Sherbrooke, Toronto, Vancouver, and Winnipeg, CanadaSee the 33 sites
Where in Canada
- Foothills Hospital/ U of CalgaryCalgary, CanadaTaking people
- Alberta Health ServicesEdmonton, CanadaTaking people
- Dalhousie UniversityHalifax, CanadaTaking people
- Queen's UniversityKingston, CanadaTaking people
- London Health Sciences CentreLondon, CanadaTaking people
- The Charles Lemoyne HospitalLongueuil, CanadaTaking people
- CHUMMontreal, CanadaTaking people
- Hôpital Maisonneuve-RosemontMontreal, CanadaTaking people
- Jewish General HospitalMontreal, CanadaTaking people
- McGill University Health CentreMontreal, CanadaTaking people
- Sacre Coeur HospitalMontreal, CanadaTaking people
- Sunnybrook Health Sciences CentreNorth York, CanadaTaking people
- Oakville Trafalgar Memorial HospitalOakville, CanadaTaking people
- Orillia Soldier's Memorial HospitalOrillia, CanadaTaking people
- Lakeridge HealthOshawa, CanadaTaking people
- The Ottawa HospitalOttawa, CanadaTaking people
- CHU de Quebec-Universite LavalQuébec, CanadaTaking people
- Red Deer Hospital;Red Deer, CanadaTaking people
- Prairie Vascular Research Inc.Regina, CanadaTaking people
- Mackenzie HealthRichmond Hill, CanadaTaking people
- Scarborough Hospital NetworkScarborough Village, CanadaTaking people
- Centre Hospitalier Universitaire de SherbrookeSherbrooke, CanadaTaking people
- Centre hospitalier universitaire de Sherbrooke (CHUS)Sherbrooke, CanadaTaking people
- Humber River HospitalToronto, CanadaTaking people
- Michael Garron HospitalToronto, CanadaTaking people
- St. Joseph's Healthcare HamiltonToronto, CanadaTaking people
- St. Joseph's Healthcare TorontoToronto, CanadaTaking people
- St. Michael's HospitalToronto, CanadaTaking people
- Trillium Health PartnersToronto, CanadaTaking people
- University Health Network - University of TorontoToronto, CanadaTaking people
- St. Paul's HospitalVancouver, CanadaTaking people
- Vancouver General HospitalVancouver, CanadaNo longer taking part
- St. Boniface General HospitalWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The University of Queensland
- Trial code
- NCT03573089
- Record updated
- 26 August 2026
- Original description
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due to heart disease, improve physical health, and be cost-effective.Read full original descriptionShow less
An Investigator-initiated, International, Multi-centre, Prospective, Randomized, Open-label, Parallel-group, Superiority, and Pragmatic Large Simple Trial (LST) to Determine Whether the Currently Recommended Strategy of Intensive Reduction of Serum Phosphate Concentration Towards the Normal Level Results in Significant Patient-centred Benefits in End-stage Kidney Disease (ESKD) Patients Receiving Dialysis.
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due to heart disease, improve physical health, and be cost-effective.
Inclusion: Age ≥45 years, or Age ≥18 years with diabetes,; ESKD on haemodialysis or peritoneal dialysis, for at least 3 months,; Currently prescribed at least one phosphate-lowering medication at any dose; Able to provide informed consent.
Exclusion: Elective kidney transplantation scheduled,; Concomitant major illness / comorbidity that may result in death in the next 6 months in the view of the treating physician,; Participation in an interventional study that is likely to affect serum phosphate concentration.